A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies or Non-Hodgkin's Lymphoma
Latest Information Update: 01 Nov 2014
At a glance
- Drugs SNX 5422 (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Esanex
- 24 Sep 2014 Pooled analysis results published in the European Journal of Cancer.
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jun 2012 New trial record